glycine has been researched along with Cardiac Output, Low in 5 studies
Cardiac Output, Low: A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mialet Perez, J | 1 |
| Rathz, DA | 1 |
| Petrashevskaya, NN | 1 |
| Hahn, HS | 1 |
| Wagoner, LE | 1 |
| Schwartz, A | 1 |
| Dorn, GW | 1 |
| Liggett, SB | 1 |
| Couzin, J | 1 |
| Abozguia, K | 1 |
| Clarke, K | 1 |
| Lee, L | 1 |
| Frenneaux, M | 1 |
| Snyder, EM | 1 |
| Turner, ST | 1 |
| Johnson, BD | 1 |
| Forster, C | 1 |
| Naik, G | 1 |
| Armstrong, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation[NCT01719367] | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 5minutes of exercise
| Intervention | beats per minute (Mean) |
|---|---|
| Atenolol: Ancestral Alleles | -10 |
| Atenolol: Variant Carriers | -13 |
After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. (NCT01719367)
Timeframe: after 10 amd 15 minutes of exercise
| Intervention | beats per minute (Mean) | |
|---|---|---|
| After 10 minutes | After 15 minutes | |
| Atenolol: Ancestral Alleles | -11 | -25.5 |
| Atenolol: Variant Carriers | -19.7 | -35.2 |
1 review available for glycine and Cardiac Output, Low
| Article | Year |
|---|---|
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Ener | 2006 |
4 other studies available for glycine and Cardiac Output, Low
| Article | Year |
|---|---|
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Arginine; Cardiac Output, Low; Echocardiography; Genetic Predi | 2003 |
American Association for the Advancement of Science meeting. DNA tells story of heart drug failure.
Topics: Adrenergic beta-Antagonists; Arginine; Cardiac Output, Low; Glycine; Humans; Pharmacogenetics; Polym | 2005 |
Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure.
Topics: Adult; Arginine; Blood Pressure; Cardiac Output, Low; Case-Control Studies; DNA; Female; Glycine; Ho | 2006 |
Noradrenaline biosynthesis and metabolism during development and recovery from pacing-induced heart failure in the dog.
Topics: Animals; Cardiac Output, Low; Cardiac Pacing, Artificial; Chromatography, High Pressure Liquid; Dihy | 1994 |